6 research outputs found
Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD
Purpose: Evaluation of three aflibercept injections at 4-week intervals in patients with neovascular AMD showing an "insufficient anatomic responseâ to prior anti-VEGF therapy with ranibizumab or bevacizumab. Methods: The retrospective analysis included 96 eyes that had received at least three intravitreal 0.5mg ranibizumab or 1.25mg bevacizumab injections over a period of no more than 4 months prior to switching to aflibercept. In addition, the selected eyes had to have evidence of persisting or increasing sub- or intraretinal fluid, observed in optical coherence tomography (OCT). All patients received a loading dose of three intravitreal 2mg aflibercept injections at 4-week intervals. Evaluation included central retinal thickness (CRT) and maximum pigment epithelium (PED) height measured by spectral domain OCT and best-corrected visual acuity (BCVA) prior to the switch of therapy and 4weeks after the third aflibercept injection. Results: A significant reduction of mean CRT (â39Îźm; pâ<â0.001) and maximum PED height (â46Îźm; pâ<â0.001) as found 4weeks after the third aflibercept injection. Eighty-two out of 96 eyes (85%) had a PED just prior to switching to aflibercept. There was an improvement in BCVA of 1.9 letters 4weeks after the last aflibercept injection; the vision gain, however, did not reach statistical significance (pâ=â0.061). The further analysis did not show any correlation of the change in CRT, maximum PED, and BCVA with the number of prior anti-VEGF treatments. Conclusion: Retinal edema and PEDs regressed significantly after switching to aflibercept in patients insufficiently responding to prior therapy with ranibizumab or bevacizumab. No correlation could be found with regard to the number of prior treatments
Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD
PURPOSE: Evaluation of three aflibercept injections at 4-week intervals in patients with neovascular AMD showing an âinsufficient anatomic responseâ to prior anti-VEGF therapy with ranibizumab or bevacizumab. METHODS: The retrospective analysis included 96 eyes that had received at least three intravitreal 0.5Â mg ranibizumab or 1.25Â mg bevacizumab injections over a period of no more than 4 months prior to switching to aflibercept. In addition, the selected eyes had to have evidence of persisting or increasing sub- or intraretinal fluid, observed in optical coherence tomography (OCT). All patients received a loading dose of three intravitreal 2Â mg aflibercept injections at 4-week intervals. Evaluation included central retinal thickness (CRT) and maximum pigment epithelium (PED) height measured by spectral domain OCT and best-corrected visual acuity (BCVA) prior to the switch of therapy and 4Â weeks after the third aflibercept injection. RESULTS: A significant reduction of mean CRT (â39Â Îźm; pâ<â0.001) and maximum PED height (â46Â Îźm; pâ<â0.001) as found 4Â weeks after the third aflibercept injection. Eighty-two out of 96 eyes (85Â %) had a PED just prior to switching to aflibercept. There was an improvement in BCVA of 1.9 letters 4Â weeks after the last aflibercept injection; the vision gain, however, did not reach statistical significance (pâ=â0.061). The further analysis did not show any correlation of the change in CRT, maximum PED, and BCVA with the number of prior anti-VEGF treatments. CONCLUSION: Retinal edema and PEDs regressed significantly after switching to aflibercept in patients insufficiently responding to prior therapy with ranibizumab or bevacizumab. No correlation could be found with regard to the number of prior treatments
Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD
Evaluation of three aflibercept injections at 4-week intervals in patients with neovascular AMD showing an "insufficient anatomic responseâ to prior anti-VEGF therapy with ranibizumab or bevacizumab. Methods: The retrospective analysis included 96 eyes that had received at least three intravitreal 0.5mg ranibizumab or 1.25mg bevacizumab injections over a period of no more than 4 months prior to switching to aflibercept. In addition, the selected eyes had to have evidence of persisting or increasing sub- or intraretinal fluid, observed in optical coherence tomography (OCT). All patients received a loading dose of three intravitreal 2mg aflibercept injections at 4-week intervals. Evaluation included central retinal thickness (CRT) and maximum pigment epithelium (PED) height measured by spectral domain OCT and best-corrected visual acuity (BCVA) prior to the switch of therapy and 4weeks after the third aflibercept injection. Results: A significant reduction of mean CRT (â39Îźm; pâ<â0.001) and maximum PED height (â46Îźm; pâ<â0.001) as found 4weeks after the third aflibercept injection. Eighty-two out of 96 eyes (85%) had a PED just prior to switching to aflibercept. There was an improvement in BCVA of 1.9 letters 4weeks after the last aflibercept injection; the vision gain, however, did not reach statistical significance (pâ=â0.061). The further analysis did not show any correlation of the change in CRT, maximum PED, and BCVA with the number of prior anti-VEGF treatments. Conclusion: Retinal edema and PEDs regressed significantly after switching to aflibercept in patients insufficiently responding to prior therapy with ranibizumab or bevacizumab. No correlation could be found with regard to the number of prior treatments
Course of disease in multifocal choroiditis lacking sufficient immunosuppression: a case report
Background:
Multifocal choroiditis with panuveitis is a rare disease. The educational merit of this case presentation results from the good documentation and the impressive ocular fundus pictures.
Case presentation:
We illustrate the 3-year course of disease in a 22-year-old myopic white woman with multifocal choroiditis with panuveitis and secondary choroidal neovascularization. The activity of the disease was evaluated clinically by optical coherence tomography and fluorescein angiography. Choroidal neovascularization was treated by intravitreal bevacizumab (2.5 mg/0.1 ml). Our patient lacked systemic therapy for the first 11 months because of noncompliance.
Conclusions:
The case is remarkable as the delayed onset of peripheral lesions and the additional existence of high myopia made diagnosis difficult. In addition, it demonstrates that full outbreak of disease with multiple central and peripheral fundus lesions and secondary choroidal neovascularization can develop without systemic treatment